Abstract
To explore the respective roles of highly active antiretroviral therapy (HAART) and alpha-interferon in improving survival of patients with AIDS-related PML, we retrospectively analyzed all patients with AIDS and PML who were referred to Johns Hopkins University HIV Neurology Program from 1985 to 2000. For 97 evaluable patients, we compared survival of those who were on HAART (three or more antiretroviral drugs) to those who were not on HAART. The effect of alpha-interferon was also studied. Multivariate analysis showed no difference in survival among patients on none, one, or two forms of antiretrovirals; however, survival was significantly greater for those on HAART. Whereas alpha-interferon use was shown to be associated with longer survival (P < 0.057), this effect was not independent of the effects of HAART. HAART significantly increases survival for patients with PML and AIDS; however, alpha-interferon does not appear to provide additional benefit.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Albrecht H, Hoffmann C, Degen O, Stoehr A, Plettenberg A, Meternskotter T, Eggers C, Stellbrink H-J (1998). Highly active antiretroviral therapy significantly improves the prognosis of patients with HIV-associated progressive multifocal leukoencephalopathy. AIDS 12(11): 1149–1154.
Berger JR, Major EO (1999). Progressive multifocal leukoencephalopathy. Sem Neurol 19(2): 193–200.
Cinque P, Casari S (1998). Progressive multifocal leukoencephalopathy, HIV, and highly active antiretroviral therapy (Letter). New Eng J Med 339(12): 848–849.
Clifford DB, Yiannoutsos C, Glicksman M, Simpson DM, Singer EJ, Piliero PJ, Marra CM, Francis GS, McArthur JC, Tyler KL, Tselis AC, Hyslop NE (1999). HAART improves prognosis in HIV-associated progressive multifocal leukoencephalopathy. Neurology 52(3): 623–625.
De Luca A, Ammassari A, Cingolani A, Giancola ML, Antinori A (1998). Disease progression and poor survival of AIDS-associated progressive multifocal leukoencephalopathy despite highly active antiretroviral therapy [letter] AIDS 12(14): 1937–1938.
De Luca A, Giancola ML, Ammassari A, Grisetti S, Paglia MG, Gentile M, Cingolani A, Murri R, Liuzzi G, Monforte AD, Aninori A (2000). The effect of potent antiretroviral therapy and JC virus load in cerebrospinal fluid on clinical outcome of patients with AIDS-associated progressive multifocal leukoencephalopathy. J Infect Dis 182: 1077–1083.
Dworkin MS, Wan PC, Hanson DL, Jones JL (1999). Progressive multifocal leukoencephalopathy: improved survival of human immunodeficiency virus-infected patients in the protease inhibitor era. J Infect Dis 180: 621–625.
Giudici B, Vaz B, Bossolasco S, Casari S, Brambilla, Lüke W, Lazzrin A, Weber, Cinque P (2000). Highly active antiretroviral therapy and progressive multifocal leukoencephalopathy: effects on cerebrospinal fluid markers of JC virus replication and immune response. Clin Infect Dis 30: 95–99.
Hall CD, Dafni U, Simpson D, Clifford D, Wetherill PE, Cohen B, McArthur J, Hollander H, Yiannoutsos C, Major E, Millar L, Timpone J (1998). Failure of Cytarabine in progressive multifocal leukoencephalopathy associated with human immunodeficiency virus infection. AIDS Clinical Trials Group 243 Team [see comments]. New Engl J Med 338(19): 1345–1351.
Happe S, Besselmann M, Matheja P, Rickert CH, Schuierer G, Reichelt D, Husstedt I-W (2000). Therapy of progressive multifocal leukoencephalopathy (PML) in AIDS with cidofovir (Vistide®). Nervenarzt 70: 935–943.
Happe S, Lünenborg N, Rickert CH, Heese C, Reichelt D, Schuierer G, Schul C, Husstedt IW (2000). Progressive multifocal leukoencephalopathy in 17 AIDS patients. Nervenarzt 71: 96–104.
Huang SS, Skolasky RL, Dal Pan GJ, Royal W III, McArthur JC (1998). Survival prolongation in HIV-associated progressive multifocal leukoencephalopathy treated with alpha-interferon: an observational study. J NeuroVirol 4(3): 324–332.
Miralles P, Berenguer J, Garcõa de Viedma D, Padilla B, Cosin J, López-Bernaldo de Quirós JC, Muñoz L, Moreno S, Bouza E (1998). Treatment of AIDS-associated progressive multifocal leukoencephalopathy with highly active antiretroviraltherapy. AIDS 12: 2467–2472.
Tantisiriwat W, Tebas P, Clifford DB, Powderly WG, Fichtenbaum CJ (1999). Progressive multifocal leukoencephalopathy in patients with AIDS receiving highly active antiretroviral therapy. Clin Infect Dis 28(5): 1152–1154.
Taoufik Y, Delfraissy JF, Gasnault J (2000). Highly active antiretroviral therapy does not improve survival of patients with high JC virus load in the cerebrospinal fluid at progressive multifocal leukoencephalopathy diagnosis [letter] AIDS 14(6): 758–759.
Tassie JM, Gasnault J, Bentata M, Deloumeaux J, Boue F, Billaud R, Costagliola D (1999). Survival improvement of AIDS-related progressive multifocal leukoencephalopathy in the era of protease inhibitors. Clinical Epidemiology Group. French Hospital Database on HIV. AIDS 13: 1881–1887.
Author information
Authors and Affiliations
Corresponding author
Additional information
This work was supported by National Institute of Health grants NS 26643 and RR 00722.
Rights and permissions
About this article
Cite this article
Geschwind, M.D., Skolasky, R.I., Royal, W.S. et al. The relative contributions of HAART and alpha-interferon for therapy of progressive multifocal leukoencephalopathy in AIDS. Journal of NeuroVirology 7, 353–357 (2001). https://doi.org/10.1080/13550280152537238
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1080/13550280152537238